Abstract
Thrombospondin-1 (TSP-1) is a matricellular glycoprotein known for being highly expressed within a tumor microenvironment, where it promotes an aggressive phenotype particularly by interacting with the CD47 cell-surface receptor. While it originates from the stromal compartment in many malignancies, melanoma is an exception as invasive and metastatic melanoma cells overexpress TSP-1. We recently demonstrated that a new molecular agent that selectively prevents TSP-1 binding to CD47, called TAX2, exhibits anti-cancer properties when administered systemically by decreasing viable tumor tissue within subcutaneous B16 melanoma allografts. At the same time, emerging evidence was published suggesting a contribution of TSP-1 in melanoma metastatic dissemination and resistance to treatment. Through a comprehensive systems biology approach based on multiple genomics and proteomics databases analyses, we first identified a TSP-1-centered interaction network that is overexpressed in metastatic melanoma. Then, we investigated the effects of disrupting TSP-1:CD47 interaction in A375 human malignant melanoma xenografts. In this model, TAX2 systemic administrations induce tumor necrosis by decreasing intra-tumoral blood flow, while concomitantly making tumors less infiltrative. Besides, TAX2 treatment also drastically inhibits B16F10 murine melanoma cells metastatic dissemination and growth in a syngeneic experimental model of lung metastasis, as demonstrated by histopathological analyses as well as longitudinal and quantitative µCT follow-up of metastatic progression. Altogether, the results obtained by combining bioinformatics and preclinical studies strongly suggest that targeting TSP-1/CD47 axis may represent a valuable therapeutic alternative for hampering melanoma spreading.
Similar content being viewed by others
Abbreviations
- 3TSR:
-
Three thrombospondin-1 type 1 repeats
- ECM:
-
Extracellular matrix
- EMT:
-
Epithelial-to-mesenchymal transition
- MST:
-
Microscale thermophoresis
- PPI:
-
Protein-protein interaction
- SIRPα:
-
Signal-regulatory protein-alpha
- SPR:
-
Surface plasmon resonance
- TSP-1:
-
Thrombospondin-1
- µCT:
-
Micro-computed tomography
References
Kazerounian S, Yee KO, Lawler J (2008) Thrombospondins in cancer. Cell Mol Life Sci 65:700–712. doi:10.1007/s00018-007-7486-z
Tuszynski G, Smith M, Rothman V et al (1992) Thrombospondin levels in patients with malignancy. Thromb Haemost 67:607–611
Naumov GN, Bender E, Zurakowski D et al (2006) A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst 98:316–325. doi:10.1093/jnci/djj068
Watnick RS, Rodriguez RK, Wang S et al (2015) Thrombospondin-1 repression is mediated via distinct mechanisms in fibroblasts and epithelial cells. Oncogene 34:2823–2835. doi:10.1038/onc.2014.228
Lin X-D, Chen S-Q, Qi Y-L et al (2012) Overexpression of thrombospondin-1 in stromal myofibroblasts is associated with tumor growth and nodal metastasis in gastric carcinoma. J Surg Oncol 106:94–100. doi:10.1002/jso.23037
McClenic BK, Mitra RS, Riser BL et al (1989) Production and utilization of extracellular matrix components by human melanocytes. Exp Cell Res 180:314–325
Straume O, Akslen LA (2001) Expression of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 159:223–235. doi:10.1016/S0002-9440(10)61688-4
Gray-Schopfer V, Wellbrock C, Marais R (2007) Melanoma biology and new targeted therapy. Nature 445:851–857. doi:10.1038/nature05661
Lito P, Rosen N, Solit DB (2013) Tumor adaptation and resistance to RAF inhibitors. Nat Med 19:1401–1409. doi:10.1038/nm.3392
Jayachandran A, Anaka M, Prithviraj P et al (2014) Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanoma. Oncotarget 5:5782–5797
Sick E, Jeanne A, Schneider C et al (2012) CD47 update: a multifaceted actor in the tumour microenvironment of potential therapeutic interest. Br J Pharmacol 167:1415–1430. doi:10.1111/j.1476-5381.2012.02099.x
Jeanne A, Schneider C, Martiny L, Dedieu S (2015) Original insights on thrombospondin-1-related antireceptor strategies in cancer. Front Pharmacol 6:252. doi:10.3389/fphar.2015.00252
Borsotti P, Ghilardi C, Ostano P et al (2015) Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. Pigment Cell Melanoma Res 28:73–81. doi:10.1111/pcmr.12319
Jeanne A, Sick E, Devy J et al (2015) Identification of TAX2 peptide as a new unpredicted anti-cancer agent. Oncotarget 6:17981–18000
Riker AI, Enkemann SA, Fodstad O et al (2008) The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1:13. doi:10.1186/1755-8794-1-13
Augustine CK, Jung S-H, Sohn I et al (2010) Gene expression signatures as a guide to treatment strategies for in-transit metastatic melanoma. Mol Cancer Ther 9:779–790. doi:10.1158/1535-7163.MCT-09-0764
Barretina J, Caponigro G, Stransky N et al (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483:603–607. doi:10.1038/nature11003
Brazma A, Parkinson H, Sarkans U et al (2003) ArrayExpress–a public repository for microarray gene expression data at the EBI. Nucleic Acids Res 31:68–71
Rhodes DR, Kalyana-Sundaram S, Mahavisno V et al (2007) Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 9:166–180
Hruz T, Laule O, Szabo G et al (2008) Genevestigator v3: a reference expression database for the meta-analysis of transcriptomes. Adv Bioinformatics 2008:420747. doi:10.1155/2008/420747
Keshava Prasad TS, Goel R, Kandasamy K et al (2009) Human protein reference database—2009 update. Nucleic Acids Res 37:D767–D772. doi:10.1093/nar/gkn892
Smoot ME, Ono K, Ruscheinski J et al (2011) Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27:431–432. doi:10.1093/bioinformatics/btq675
Breuer K, Foroushani AK, Laird MR et al (2013) InnateDB: systems biology of innate immunity and beyond–recent updates and continuing curation. Nucleic Acids Res 41:D1228–1233. doi:10.1093/nar/gks1147
Launay G, Salza R, Multedo D et al (2015) MatrixDB, the extracellular matrix interaction database: updated content, a new navigator and expanded functionalities. Nucleic Acids Res 43:D321–327. doi:10.1093/nar/gku1091
Uhlén M, Fagerberg L, Hallström BM, et al (2015) Proteomics. Tissue-based map of the human proteome. Science 347:1260419. doi: 10.1126/science.1260419
Seidel SAI, Dijkman PM, Lea WA et al (2013) Microscale thermophoresis quantifies biomolecular interactions under previously challenging conditions. Methods 59:301–315. doi:10.1016/j.ymeth.2012.12.005
Kretschmer L, Beckmann I, Thoms K-M et al (2006) Factors predicting the risk of in-transit recurrence after sentinel lymphonodectomy in patients with cutaneous malignant melanoma. Ann Surg Oncol 13:1105–1112. doi:10.1245/ASO.2006.07.020
Langlois B, Perrot G, Schneider C et al (2010) LRP-1 promotes cancer cell invasion by supporting ERK and inhibiting JNK signaling pathways. PLoS One 5:e11584. doi:10.1371/journal.pone.0011584
Perrot G, Langlois B, Devy J et al (2012) LRP-1–CD44, a new cell surface complex regulating tumor cell adhesion. Mol Cell Biol 32:3293–3307. doi:10.1128/MCB.00228-12
Zaslavsky A, Baek K-H, Lynch RC et al (2010) Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood 115:4605–4613. doi:10.1182/blood-2009-09-242065
Zhang X, Kazerounian S, Duquette M et al (2009) Thrombospondin-1 modulates vascular endothelial growth factor activity at the receptor level. FASEB J 23:3368–3376. doi:10.1096/fj.09-131649
Gaustad J-V, Simonsen TG, Andersen LMK, Rofstad EK (2015) Thrombospondin-1 domain-containing peptide properdistatin improves vascular function in human melanoma xenografts. Microvasc Res 98:159–165. doi:10.1016/j.mvr.2014.02.005
De Bock K, Mazzone M, Carmeliet P (2011) Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8:393–404. doi:10.1038/nrclinonc.2011.83
Kaur S, Soto-Pantoja DR, Stein EV et al (2013) Thrombospondin-1 signaling through CD47 inhibits self-renewal by regulating c-myc and other stem cell transcription factors. Sci Rep. doi:10.1038/srep01673
Roberts DD, Kaur S, Soto-Pantoja DR (2015) Therapeutic targeting of the thrombospondin-1 receptor CD47 to treat liver cancer. J Cell Commun Signal 9:101–102. doi:10.1007/s12079-015-0283-9
Lee TK-W, Cheung VC-H, Lu P et al (2014) Blockade of CD47-mediated cathepsin S/protease-activated receptor 2 signaling provides a therapeutic target for hepatocellular carcinoma. Hepatology 60:179–191. doi:10.1002/hep.27070
Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24:225–232. doi:10.1016/j.coi.2012.01.010
McCracken MN, Cha AC, Weissman IL (2015) Molecular pathways: activating t cells after cancer cell phagocytosis from blockade of CD47 “Don’t Eat Me” signals. Clin Cancer Res 21:3597–3601. doi:10.1158/1078-0432.CCR-14-2520
Soto-Pantoja DR, Terabe M, Ghosh A et al (2014) CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res 74:6771–6783. doi:10.1158/0008-5472.CAN-14-0037-T
Kim MJ, Lee J-C, Lee J-J et al (2008) Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol 29:28–34. doi:10.1159/000132568
Weng T-Y, Huang S-S, Yen M-C et al (2014) A novel cancer therapeutic using thrombospondin 1 in dendritic cells. Mol Ther 22:292–302. doi:10.1038/mt.2013.236
Fischer KR, Durrans A, Lee S et al (2015) Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature. doi:10.1038/nature15748
Zheng X, Carstens JL, Kim J et al (2015) Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527:525–530. doi:10.1038/nature16064
Hirata E, Girotti MR, Viros A et al (2015) Intravital imaging reveals how BRAF inhibition generates drug-tolerant microenvironments with high integrin β1/FAK signaling. Cancer Cell 27:574–588. doi:10.1016/j.ccell.2015.03.008
Filleur S, Volpert OV, Degeorges A et al (2001) In vivo mechanisms by which tumors producing thrombospondin 1 bypass its inhibitory effects. Genes Dev 15:1373–1382. doi:10.1101/gad.193501
Acknowledgments
The authors acknowledge supports from Centre National de la Recherche Scientifique (CNRS), Région Champagne-Ardenne and SATT Nord. AJ was recipient of grants from the Ministère de l’Enseignement Supérieur et de la Recherche (2010-2013). The authors acknowledge A. Thomachot for editorial assistance.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Jeanne, A., Boulagnon-Rombi, C., Devy, J. et al. Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide. Clin Exp Metastasis 33, 637–649 (2016). https://doi.org/10.1007/s10585-016-9803-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-016-9803-0